RegenXBio sells Hunter syndrome gene therapy's U.S., Asia commercial rights for $110M upfront

With an FDA approval submission for RegenXBio’s Hunter syndrome gene therapy already underway, the biopharma has now found a commercialization partner for both the U.S. and Asian markets.